Entities / Company
Spectris.
British instrumentation and measurement specialist
- Reports this week
- 0
- Active events
- 0
- Connections
- 11
What's happening
Gone quiet
No new reports in 90+ days-
Apollo approached Bodycote with an acquisition offer, which was subsequently withdrawn. The conditional approach was made on June 16, 2026.Some support1 report
-
Leading companies in the global DAQ market are National Instruments, Keysight Technologies, and Spectris (as of August 4, 2025).Some support1 report
-
KKR offered $5.6 billion on July 3, 2025, to acquire Spectris.Speculative1 report
-
Spectris presented clinical trial data in Cambridge, Massachusetts on July 28, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Spectris this week
News at the entities that move Spectris most-
Louisiana Shared contextWWNO covered Louisiana's coastal restoration needs and questioned officials about reproductive health issues.Moves Spectris
-
Brookfield Wealth Solutions TransactionalBrookfield Wealth Solutions and Paysign are competing for investment capital, while MarketBeat provides analyst recommendations for Paysign.Moves Spectris
Connections
The 3 strongest of 11, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Louisiana Shared context
Spectris is currently being subjected to an experimental treatment within the market context of Louisiana.
-
Advent International Transactional
Advent International acquired Spectris following a takeover bid.
-
Brookfield Wealth Solutions Transactional
The relationship is currently under observation regarding a proposed acquisition offer.
History
Events by the month they beganJune 2026
4 events- Apollo approached Bodycote with an acquisition offer, which was subsequently withdrawn. The conditional approach was made on June 16, 2026.
- Leading companies in the global DAQ market are National Instruments, Keysight Technologies, and Spectris (as of August 4, 2025).
- KKR offered $5.6 billion on July 3, 2025, to acquire Spectris.
- Spectris presented clinical trial data in Cambridge, Massachusetts on July 28, 2025.